(Q30251865)

13 June 2017

title

Alzheimer's disease (English)

1 reference

13 June 2017

1 reference

Giovanni B Frisoni

5

0 references

Philip Scheltens

series ordinal

1

object named as

Philip Scheltens

1 reference

13 June 2017

2

Kaj Blennow

1 reference

13 June 2017

3

Monique M B Breteler

1 reference

13 June 2017

Bart de Strooper

4

1 reference

13 June 2017

Stephen Salloway

series ordinal

6

1 reference

13 June 2017

Wiesje Maria Van der Flier

series ordinal

7

1 reference

13 June 2017

language of work or name

English

0 references

publication date

23 February 2016

1 reference

13 June 2017

1 reference

13 June 2017

volume

388

1 reference

13 June 2017

issue

10043

1 reference

13 June 2017

page(s)

505-517

1 reference

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

13 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Alzheimer's disease first symptoms are age dependent: Evidence from the NACC dataset

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Shining a light on posterior cortical atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Dementia in western Europe: epidemiological evidence and implications for policy making

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

The global prevalence of dementia: a systematic review and metaanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Estimating the burden of early onset dementia; systematic review of disease prevalence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

New insights into the dementia epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Period, birth cohort and prevalence of dementia in mainland China, Hong Kong and Taiwan: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Prevalence and trends of dementia in Korea: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Epidemiology of dementia in Asia: insights on prevalence, trends and novel risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Cardiovascular and cognitive fitness at age 18 and risk of early-onset dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Diabetes in midlife and cognitive change over 20 years: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Influence of population versus convenience sampling on sample characteristics in studies of cognitive aging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

What is a representative brain? Neuroscience meets population science

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Potential for primary prevention of Alzheimer's disease: an analysis of population-based data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

APOE and Alzheimer disease: a major gene with semi-dominant inheritance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Human apoE isoforms differentially regulate brain amyloid-β peptide clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Apolipoprotein e sets the stage: response to injury triggers neuropathology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Apolipoprotein E controls cerebrovascular integrity via cyclophilin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Genetics of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Alzheimer's disease risk genes and mechanisms of disease pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

REST and stress resistance in ageing and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Alteration of the microRNA network during the progression of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

TREM2 Variants in Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Much of late life cognitive decline is not due to common neurodegenerative pathologies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

The mechanism of γ-Secretase dysfunction in familial Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Self-propagation of pathogenic protein aggregates in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Decreased clearance of CNS beta-amyloid in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Distinct tau prion strains propagate in cells and mice and define different tauopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Neurodegeneration: Alzheimer's disease under strain.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Neuroscience. Promiscuous Alzheimer's amyloid: yet another partner

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

η-Secretase processing of APP inhibits neuronal activity in the hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

BACE1 inhibitor drugs in clinical trials for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

An atomic structure of human γ-secretase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

A three-dimensional human neural cell culture model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

CSF biomarker variability in the Alzheimer's Association quality control program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Plasma phospholipids identify antecedent memory impairment in older adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

The future of blood-based biomarkers for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

A candidate plasma protein classifier to identify Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Plasma tau levels in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

The clinical use of structural MRI in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Imaging markers for Alzheimer disease: which vs how

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Training labels for hippocampal segmentation based on the EADC-ADNI harmonized hippocampal protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Brain microbleeds and Alzheimer's disease: innocent observation or key player?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Meta-analysis based SVM classification enables accurate detection of Alzheimer's disease across different clinical centers using FDG-PET and MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Functional network disruption in the degenerative dementias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Clinical amyloid imaging in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Cerebrovascular disease, β-amyloid, and cognition in aging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Tau imaging: early progress and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

The evolution of preclinical Alzheimer's disease: implications for prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Regulatory innovation and drug development for early-stage Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Charting a path toward combination therapy for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901124-1

7 January 2021

10.1016/S0140-6736(15)01124-1

Identifiers

DOI

1 reference

13 June 2017

1 reference